Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y2IE
|
|||
| Former ID |
DAP000445
|
|||
| Drug Name |
Cefuroxime
|
|||
| Synonyms |
Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute bronchitis [ICD-11: CA42] | Approved | [1] | |
| Therapeutic Class |
Antibiotics
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H16N4O8S
|
|||
| Canonical SMILES |
CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
|
|||
| InChI |
1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
|
|||
| InChIKey |
JFPVXVDWJQMJEE-IZRZKJBUSA-N
|
|||
| CAS Number |
CAS 55268-75-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10308, 7847978, 8139982, 14833063, 14881773, 24892692, 25819900, 43176102, 50050864, 56041334, 57260152, 57264411, 57387187, 57654015, 77146479, 89736081, 92713907, 117664401, 121363576, 124766425, 126629706, 126655800, 126686329, 135004234, 137267224, 152101191, 162225020, 163316243, 164788191, 170524605, 175265786, 175611978, 179316275, 187072187, 196112116, 223439274, 223674139, 227008553, 252122164, 252402066
|
|||
| ChEBI ID |
CHEBI:3515
|
|||
| ADReCS Drug ID | BADD_D00407 ; BADD_D00409 | |||
| SuperDrug ATC ID |
J01DC02; S01AA27
|
|||
| SuperDrug CAS ID |
cas=055268752
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
|
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Staphylococcus was decreased by Cefuroxime axetil. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Cefuroxime sodium salt (adjusted p-values: 3.53E-03). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Cefuroxime sodium salt (adjusted p-values: 1.44E-06). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Cefuroxime sodium salt (adjusted p-values: 4.05E-06). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Cefuroxime sodium salt (adjusted p-values: 2.73E-07). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Cefuroxime sodium salt (adjusted p-values: 5.51E-07). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Cefuroxime sodium salt (adjusted p-values: 3.53E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was decreased by Cefuroxime axetil (p < 0.01). | |||
|
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium adolescentis was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium longum was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Cefuroxime sodium salt (adjusted p-values: 4.93E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Citrobacter
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Citrobacter was increased by Cefuroxime axetil. | |||
|
Studied Microbe: Enterobacter
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacter was increased by Cefuroxime axetil. | |||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacteriaceae was decreased by Cefuroxime axetil. | |||
|
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Escherichia was decreased by Cefuroxime axetil. | |||
|
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli ED1a was decreased by Cefuroxime sodium salt (adjusted p-values: 5.75E-06). | |||
|
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli IAI1 was decreased by Cefuroxime sodium salt (adjusted p-values: 4.93E-07). | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Klebsiella was increased by Cefuroxime axetil. | |||
|
Studied Microbe: Salmonella
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Salmonella was increased by Cefuroxime axetil. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Erysipelatoclostridium ramosum was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Cefuroxime sodium salt (adjusted p-values: 9.12E-07). | |||
|
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridium difficile was increased by Cefuroxime. | |||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Cefuroxime sodium salt (adjusted p-values: 6.45E-07). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Cefuroxime sodium salt (adjusted p-values: 1.55E-05). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Cefuroxime sodium salt (adjusted p-values: 1.68E-04). | |||
|
Studied Microbe: Lacrimispora saccharolytica
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lacrimispora saccharolytica was decreased by Cefuroxime sodium salt (adjusted p-values: 2.87E-07). | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Cefuroxime sodium salt (adjusted p-values: 1.75E-05). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Cefuroxime sodium salt (adjusted p-values: 1.32E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Cefuroxime sodium salt (adjusted p-values: 1.18E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was increased by Cefuroxime. | |||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was increased by Cefuroxime axetil. | |||
|
Studied Microbe: Enterococcus durans
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus durans was decreased by Cefuroxime axetil (p < 0.01). | |||
|
Studied Microbe: Enterococcus faecalis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus faecalis was decreased by Cefuroxime axetil (p < 0.01). | |||
|
Studied Microbe: Enterococcus faecium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus faecium was decreased by Cefuroxime axetil (p < 0.01). | |||
|
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lactobacillus paracasei was decreased by Cefuroxime sodium salt (adjusted p-values: 4.70E-05). | |||
|
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus parasanguinis was decreased by Cefuroxime sodium salt (adjusted p-values: 5.51E-07). | |||
|
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus salivarius was decreased by Cefuroxime sodium salt (adjusted p-values: 5.52E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Veillonella parvula was decreased by Cefuroxime sodium salt (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Akkermansia muciniphila was decreased by Cefuroxime sodium salt (adjusted p-values: 1.09E-04). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Target Info | Binder | [7] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis. 1997 Sep;25(3):729-32. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Betalactam therapy and intestinal flora. J Chemother. 1995 May;7 Suppl 1:25-31. | |||
| REF 5 | The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother. 1985 Mar;15(3):319-26. | |||
| REF 6 | The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. J Antimicrob Chemother. 1994 Jul;34(1):127-38. | |||
| REF 7 | Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.